Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1148/radiol.2372031994
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nakamoto, Y.
Right arrow Articles by Wahl, R. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nakamoto, Y.
Right arrow Articles by Wahl, R. L.
(Radiology 2005;237:627-634.)
© RSNA, 2005


Nuclear Medicine

CT Appearance of Bone Metastases Detected with FDG PET as Part of the Same PET/CT Examination1

Yuji Nakamoto, MD, PhD, Christian Cohade, MD, Mitsuaki Tatsumi, MD, PhD, Dima Hammoud, MD and Richard L. Wahl, MD

1 From the Division of Nuclear Medicine, Johns Hopkins School of Medicine, 601 N Caroline St, Room 3223A, Baltimore, MD 21287-0817. Received December 8, 2003; revision requested February 12, 2004; final revision received December 9; accepted January 26, 2005. Address correspondence to R.L.W.

PURPOSE: To retrospectively evaluate lesion findings at computed tomography (CT) performed as part of a combined positron emission tomography (PET)/CT examination in patients suspected of having metastatic bone lesions—lesions that were detected with fluorine 18 fluorodeoxyglucose (FDG) PET as part of the same examination—and to correlate the CT and FDG PET findings.

MATERIALS AND METHODS: This HIPAA-compliant study had institutional review board approval, and the need for patient informed consent was waived. Three hundred fifty-nine consecutive patients (191 male patients, 168 female patients; mean age, 56.9 years; age range, 8–92 years) underwent PET/CT. PET images were first reviewed by nuclear medicine physicians who had no clinical information regarding the presence or absence of bone metastasis by using a five-point grading system (0, a lesion was definitely negative for metastasis; 1, a lesion was probably negative; 2, a lesion was equivocal; 3, a lesion was probably positive; and 4, a lesion was definitely positive). For lesions assigned a grade of 3 or 4 at PET, CT characteristics such as the presence or absence of morphologic changes or accompanying findings (including bone destruction) were assessed by radiologists on the CT images obtained during the same imaging session.

RESULTS: One hundred seventy-nine lesions in 55 patients were considered to be probable or definite bone metastases at PET. One hundred thirty-three of these lesions in 33 patients were clinically confirmed to be bone metastases at follow-up and/or histopathologic examination. CT revealed osteolytic changes in 41 (31%) and osteoblastic changes in 21 (16%) of the 133 lesions, but no or nonspecific changes were seen at CT in 49 (37%) and 22 lesions (17%), respectively. Of the 179 lesions suspected at PET, 46 ultimately proved to be nonosseous or false-positive for bone metastasis. Of these 46 lesions, 38 were not located in the bone but in adjacent tissues such as the pleura.

CONCLUSION: CT images obtained as part of PET/CT scanning were useful in yielding the precise location of bone lesions and thus helping avoid misdiagnosis of bone metastasis; however, CT revealed morphologic changes in only half of the lesions assigned a grade of 3 or 4 at PET.

© RSNA, 2005




This article has been cited by other articles:


Home page
Ann. Thorac. Surg.Home page
R. S. Andrade, J. J. Blondet, T. Kast, J. Jessurun, and M. A. Maddaus
Evaluation of isolated rib lesions with radionuclide-guided biopsy.
Ann. Thorac. Surg., October 1, 2008; 86(4): 1111 - 1114.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
U. Tateishi, C. Gamez, S. Dawood, H. W. D. Yeung, M. Cristofanilli, and H. A. Macapinlac
Bone Metastases in Patients with Metastatic Breast Cancer: Morphologic and Metabolic Monitoring of Response to Systemic Therapy with Integrated PET/CT
Radiology, April 1, 2008; 247(1): 189 - 196.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
Y. Du, I. Cullum, T. M. Illidge, and P. J. Ell
Fusion of Metabolic Function and Morphology: Sequential [18F]Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography Studies Yield New Insights Into the Natural History of Bone Metastases in Breast Cancer
J. Clin. Oncol., August 10, 2007; 25(23): 3440 - 3447.
[Abstract] [Full Text] [PDF]


Home page
Arch Otolaryngol Head Neck SurgHome page
D. Basu, B. A. Siegel, D. J. McDonald, and B. Nussenbaum
Detection of Occult Bone Metastases From Head and Neck Squamous Cell Carcinoma: Impact of Positron Emission Tomography Computed Tomography With Fluorodeoxyglucose F 18
Arch Otolaryngol Head Neck Surg, August 1, 2007; 133(8): 801 - 805.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
A. V. Taira, R. J. Herfkens, S. S. Gambhir, and A. Quon
Detection of Bone Metastases: Assessment of Integrated FDG PET/CT Imaging
Radiology, April 1, 2007; 243(1): 204 - 211.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
O. Israel and A. Kuten
Early Detection of Cancer Recurrence: 18F-FDG PET/CT Can Make a Difference in Diagnosis and Patient Care
J. Nucl. Med., January 1, 2007; 48(1_suppl): 28S - 35S.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
RADIOLOGY RADIOGRAPHICS RSNA JOURNALS ONLINE
Copyright © 2005 by the Radiological Society of North America.